Loading
Loading
Research Overview
PTH/PTHrP receptor agonists that promote osteoblast activity over osteoclast activity, increasing bone mineral density; teriparatide is a PTH(1-34) fragment; abaloparatide is a PTHrP analogue with greater selectivity for the RG conformation reducing hypercalcaemia risk.
Overview
Teriparatide is a recombinant peptide comprising the first 34 amino acids of parathyroid hormone (PTH 1-34), the biologically active fragment of the full 84-amino acid PTH molecule. It acts as a PTH1R agonist with a well-characterised receptor engagement profile studied extensively in preclinical bone biology models. Abaloparatide is a synthetic analogue of PTHrP (PTH-related protein) 1-34, sharing the same receptor target but with a distinct binding mode that has been characterised preclinically for differential effects on PTH1R signalling conformations.
Preclinical bone biology research has used both compounds to study the mechanisms by which intermittent PTH1R activation promotes bone formation, distinguishing anabolic (bone-building) effects from catabolic bone resorption effects seen with continuous PTH1R stimulation. Animal model skeletal studies have used micro-CT, histomorphometry, and bone biomechanical testing to characterise changes in trabecular and cortical bone architecture under both compound treatment conditions.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, abaloparatide and teriparatide (pth receptor agonists) bone biology has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
PTH/PTHrP receptor agonists that promote osteoblast activity over osteoclast activity, increasing bone mineral density; teriparatide is a PTH(1-34) fragment; abaloparatide is a PTHrP analogue with greater selectivity for the RG conformation reducing hypercalcaemia risk.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.